Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Monsanto Co. -- Ignore unavailable to you. Want to Upgrade?

To: Chihcheng Hsu who wrote (673)	12/1/1998 5:18:00 PM
From: Dan Spillane	Respond to of 2539

The approval is "recommended" but not yet "official" for the two major classes. The third class (acute pain) is put off temporarily, not cancelled. This is about the best news I had hoped for -- the money is in the first two, and the acute pain thing would mean even more money. Perhaps when the the official word comes, people will become interested in the stock. Can't imagine Merck stock going up on this, Monsanto down. Just plain doesn't make sense, particularly with the news that Monsanto's drug works with one pill a day... that used to be the advantage the Merck drug had. Often the stock market is a little "off" in valuations, but these tend to adjust. I think the negative Reuters news is throwing everyone, and others just were in until the approval went through. FORGET about the possible billion in sales next year, to them.